Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Trump-Xi Talk AI, Xi Calls for US to Oppose Taiwan Independence, More 8 min · 25 Sep 2026 · Bloomberg News Now

Sharp or Square - SHARP NFL Week 3 Bets - Patriots-Jaguars, Texans-Colts and more 1h 22m · 25 Sep 2026 · The Herd with Colin Cowherd

The Buffalo Curse, a Mega-Mailbag, QB Roulette, and Week 3 Picks With Joe House and Tom Pelissero 2h 4m · 25 Sep 2026 · The Bill Simmons Podcast

The Iran War and the Looming Economic Collapse (w/ John Mearsheimer) | TCHR 57 min · 25 Sep 2026 · The Chris Hedges Report

1213: Day 1 of the '26 Presidents Cup 1h 21m · 25 Sep 2026 · No Laying Up - Golf Podcast

S13 EP20: A Couple of Vanilla Dudes 45 min · 25 Sep 2026 · Parenting Hell with Rob Beckett and Josh Widdicombe

Report any issue

Source

Recorded10 Feb 2026

Publisheraudiomedica.com ↗

Handlerec:19315681

Show notes

This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding tucatinib to trastuzumab and pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer as first-line maintenance therapy, with no new safety signals. This small molecule HER2 inhibitor offers a promising new option.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in